Clinical Trial Update: Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. [Phase 2]

View source ↗

Summary

Phase 2 trial investigating orelabrutinib as consolidation and maintenance therapy in treatment-naïve marginal zone lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Marginal Zone Lymphoma (MZL) | Phase 2 | Status: RECRUITING